Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.

摘要: Background Although the 13-valent pneumococcal conjugate vaccine (PCV13) showed good efficacy against disease in CAPiTA trial, 23-valent polysaccharide vaccination (PPSV23) program has been ongoing for older adults aged ≥ 65 years Korea since May of 2013. This study aimed to evaluate cost-effectiveness current strategy (a single-dose PPSV23 vaccination) compared a PCV13 and sequential PCV13-PPSV23 vaccinations elderly population years. Methods Using Markov model, incremental ratios (ICERs) three strategies were assessed societal context. The transition probabilities, utility weights estimate quality adjusted life year (QALY), treatment costs either calculated or cited from published data Health Insurance Review Assessment Service. Simulations performed hypothetical cohorts Korean 19 years. effectiveness was Cochrane report, while gathered trial. Results Current cost-effective (ICER, $25,786 per QALY). However, administration as substitute shown be more than $797 Sequential also people In sensitivity analysis assuming significant (50%) non-bacteremic pneumonia, superior terms cost-effectiveness. Conclusion The results suggest that is subjects strategy. When complete obtained 2018 on maximal herd effects childhood immunization, incidence pneumonia need reassessed.